The US Food and Drug Administration (FDA) has approved Perrigo’s abbreviated new drug application for ketoconazole foam, 2%, a generic equivalent to Extina ketoconazole foam, 2%.

Ketoconazole foam, 2%, is indicated as a topical treatment of seborrheic dermatitis in immunocompetent patients aged 12 or older.

Perrigo chairman and CEO Joseph Papa said the launch reflects the company’s continuing investment in new products.

“It is an example of the partnership we have with Cobrek to develop foam products, which is a key product category for our Rx business,” Papa said.